BioWorld

Jan. 20, 2009

Peptimmune, Novartis Sign $500M Deal for MS Drug

Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today) Read More

Drop in Manufacturing Demand Prompts Cuts to XOMA's Staff

Will Health Care Reform Save Biotech, Economy

NewCo News: Carolus Therapeutics Wants to be King of Cytokine Targeting

Holiday Notice

Corrections & Clarifications

FDA Issues Final Guidance on Rules for GE Animals

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 9, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...